Lipoprotein(a) in Health and Disease

References

• Berg K. A new serum type system in man—the Lp system. Acta Pathol Microbiol Scand 1963; 59: 369–82
   PubMedGoogle Scholar
• McLean J W, Tomlinson J E, Kuang W-J, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature (London) 1987; 300: 132–7
   Web of Science ®Google Scholar
• Murray J C, Buetow K H, Donovan M, et al. Linkage disequilibrium of plasminogen polymorphisms and assignment of the gene to human chromosome 6q26–6q27. Am J Hum Genet 1987; 40: 338–50
   PubMed Web of Science ®Google Scholar
• Kratzin H, Armstrong V W, Niehaus M, et al. Structural relationship of an apolipoprotein(a) phenotype (570 kDa) to plasminogen: homologous kringle domains are linked by carbohydraterich regions. Biol Chem Hoppe Seyler 1987; 368: 1533–44
   PubMedGoogle Scholar
• Lawn R M, Boonmark N W, Schwartz K, et al. The recurring evolution of lipoprotein(a)—Insights from cloning of hedgehog apolipoprotein(a). J Biol Chem 1995; 270: 24004–9
   PubMedGoogle Scholar
• Lackner C, Cohen JC, Hobbs HH. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 1993; 2: 933–40
   PubMed Web of Science ®Google Scholar
• Van der Hoek Y Y, Wittekoek M E, Beisiegel U, et al. The apolipoprotein(a) kringle IV repeats that differ from the major repeat kringle are present in variably sized isoforms. Hum Mol Genet 1993; 2: 361–6
   PubMed Web of Science ®Google Scholar
• Scanu AM. Identification of mutations in human apolipoprotein(a) kringle 4–37 from the study of the DNA of peripheral blood lymphocytes: relevance to the role of lipoprotein(a) in atherothrombosis. Am J Cardiol 1995; 75: 58B–61B.
   PubMedGoogle Scholar
• Klezovitch O, Scanu AM. Lys and fibrinogen binding of wild-type (Trp72) and mutant (Arg72) human apo(a) kringle IV-10 expressed inE. coliand CHO cells. Arterioscler Thromb Vasc Biol 1996; 16: 392–8
   PubMedGoogle Scholar
• Gaw A, Hobbs HH. Molecular genetics of lipoprotein(a): new pieces to the puzzle. Curr Opin Lipidol 1994; 5: 159–65
   Google Scholar
• Kraft H G, Menzel H J, Hoppichler F, et al. Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. J Clin Invest 1989; 83: 137–42
   PubMed Web of Science ®Google Scholar
• Koschinsky M L, Côté GP, Gabel B, et al. Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100. J Biol Chem 1993; 268: 19819–25
   PubMed Web of Science ®Google Scholar
• Brunner C, Kraft H G, Utermann G, et al. Cys(4057) of apolipoprotein(a) is essential for lipoprotein(a) assembly. Proc Natl Acad Sci USA 1993; 90: 11643–7
   PubMed Web of Science ®Google Scholar
• Frank S, Krasznai K, Durovic S, et al. High-level expression of various apolipoprotein(a) isoforms by “transferrinfection”: the role of kringle IV sequences in the extracellular association with low-density lipoprotein. Biochemistry 1994; 33: 12329–39
   PubMed Web of Science ®Google Scholar
• McCormick S PA, No J K, Taylor S, et al. Mutagenesis of the human apolipoprotein B gene in a yeast artificial chromosome reveals the site of attachment for apolipoprotein(a). Proc Natl Acad Sci USA 1995; 92: 10147–51
   PubMedGoogle Scholar
• White A L, Lanford RE. Biosynthesis and metabolism of lipoprotein(a). Curr Opin Lipidol 1995; 6: 75–80
   PubMedGoogle Scholar
• White A L, Lanford RE. Apo(a) folding in the endoplasmatic reticulum. Circulation 1995; 92: I–2, Suppl. I., Abstr
   Google Scholar
• Edelstein C, Mandala M, Pfaffinger D, et al. Determinants of lipoprotein(a) assembly: A study of wild-type and mutant apolipoprotein(a) phenotypes isolated from human and rhesus monkey lipoprotein(a) under mild reductive conditions. Biochemistry 1995; 34: 16483–92
   PubMedGoogle Scholar
• Slunga L, Johnson O, Dahlén GH. Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin. Eur J Clin Pharmacol 1992; 43: 369–73
   PubMed Web of Science ®Google Scholar
• O'Connor P, Cooke T, Feely J. Effects of HMG Co-A reductase inhibitors on lipids and lipoprotein(a) in hypercholesterolaemia. Drug Invest 1992; 4: 227–31
   Google Scholar
• Rader D J, Mann W A, Cain W, et al. The low-density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest 1995; 95: 1403–8
   PubMed Web of Science ®Google Scholar
• Krempler F, Kostner G M, Bolzano K, et al. Turnover of lipoprotein(a) in man. J Clin Invest 1980; 65: 1483–90
   PubMed Web of Science ®Google Scholar
• Rader D J, Cain W, Zech L A, et al. Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein(a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest 1993; 91: 443–7
   PubMed Web of Science ®Google Scholar
• Utermann G, Menzel H J, Kraft H G, et al. Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987; 80: 458–65
   PubMed Web of Science ®Google Scholar
• Utermann G. The mysteries of lipoprotein(a). Science 1989; 246: 904–10
   PubMed Web of Science ®Google Scholar
• Utermann G, Hoppichler F, Dieplinger H, et al. Defects in the low-density lipoprotein receptor gene affect lipoprotein (a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis. Proc Natl Acad Sci USA 1989; 86: 4171–4
   PubMedGoogle Scholar
• Sandholzer C, Hallman D M, Saha N, et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet 1991; 86: 607–14
   PubMed Web of Science ®Google Scholar
• Jenner J L, Ordovas J M, Lamon-Fava S, et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels: The Framingham Offspring Study. Circulation 1993; 87: 1135–41
   PubMed Web of Science ®Google Scholar
• Farish E, Rolton H A, Barnes J F, et al. Lipoprotein(a) and postmenopausal oestrogen. Acta Endocrinol (Copenhagen) 1993; 129: 225–8
   PubMedGoogle Scholar
• Kamboh M I, Ferrell RE, Kottke BA. Expressed hypervariable polymorphism of apolipoprotein (a). Am J Hum Genet 1991; 49: 1063–74
   PubMed Web of Science ®Google Scholar
• Marcovina S M, Zhang Z H, Gaur V P, et al. Identification of 34 apolipoprotein(a) isoforms: differential expression of apolipoprotein(a) alleles between American blacks and whites. Biochem Biophys Res Commun 1993; 191: 1192–6
   PubMed Web of Science ®Google Scholar
• Utermann G, Haibach C, Trommsdorff M, et al. Genetic architecture of the atherogenic lipoprotein(a). Ann NY Acad Sci 1995; 748: 301–12
   PubMedGoogle Scholar
• Lackner C, Boerwinkle E, Leffert C C, et al. Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest 1991; 87: 2153–61
   PubMed Web of Science ®Google Scholar
• Kraft H G, Köchl S, Menzel H J, et al. The apolipoprotein(a) gene: a transcribed hypervariable locus controlling plasma lipoprotein(a) concentration. Hum Genet 1992; 90: 220–30
   PubMed Web of Science ®Google Scholar
• Kraft H G, Lingenhel A, Bader G, et al. The relative electrophoretic mobility of apo(a) isoforms depends on the gel system: proposal of a nomenclature for apo(a) phenotypes. Atherosclerosis 1996; 125: 53–61
   PubMedGoogle Scholar
• Boerwinkle E, Menzel H J, Kraft H G, et al. Genetics of the quantitative Lp(a) lipoprotein trait. III. Contribution of Lp(a) glycoprotein phenotypes to normal lipid variation. Hum Genet 1989; 82: 73–8
   PubMed Web of Science ®Google Scholar
• Boerwinkle E, Leffert C C, Lin J, et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992; 90: 52–60
   PubMed Web of Science ®Google Scholar
• Austin M A, Sandholzer C, Selby J V, et al. Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes. Am J Hum Genet 1992; 51: 829–40
   PubMed Web of Science ®Google Scholar
• Mooser V, Mancini F P, Bopp S, et al. Sequence polymorphisms in the apo(a) gene associated with specific levels of Lp(a) in plasma. Hum Mol Genet 1995; 4: 173–81
   PubMedGoogle Scholar
• Trommsdorff M, Köchl S, Lingenhel A, et al. A pentanucleotide repeat polymorphism in the 5′ control region of the apolipoprotein(a) gene is associated with lipoprotein(a) plasma concentrations in Caucasians. J Clin Invest 1995; 96: 150–7
   PubMed Web of Science ®Google Scholar
• Mancini F P, Mooser V, Guerra R, et al. Sequence microheterogeneity in apolipoprotein(a) gene repeats and the relationship to plasma Lp(a) levels. Hum Mol Genet 1995; 4: 1535–42
   PubMedGoogle Scholar
• Zysow B R, Lindahl G E, Wade D P, et al. C/T polymorphism in the 5′ untranslated region of the apolipoprotein(a) gene introduces an upstream ATG and reduces in vitro translation. Arterioscler Thromb 1995; 15: 58–64
   PubMedGoogle Scholar
• Howard G C, Pizzo SV. Lipoprotein(a) and its role in atherothrombotic disease. Lab Invest 1993; 69: 373–86
   PubMed Web of Science ®Google Scholar
• Harpel P C, Hermann A, Zhang X X, et al. Lipoprotein(a), plasmin modulation, and atherogenesis. Thromb Haemost 1995; 74: 382–6
   PubMedGoogle Scholar
• Harpel P C, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA 1989; 86: 3847–51
   PubMedGoogle Scholar
• Miles L A, Fless G M, Levin E G, et al. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature (London) 1989; 339: 301–3
   PubMed Web of Science ®Google Scholar
• Hajjar K A, Gavish D, Breslow J L, et al. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature (London) 1989; 339: 303–5
   PubMed Web of Science ®Google Scholar
• Harpel P C, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 1992; 89: 10193–7
   PubMed Web of Science ®Google Scholar
• Edelberg J M, Gonzalez-Gronow M, Pizzo SV. Lipoprotein(a) inhibits streptokinase-mediated activation of human plasminogen. Biochemistry 1989; 28: 2370–4
   PubMedGoogle Scholar
• Karádi I, Kostner G M, Gries A, et al. Lipoprotein(a) and plasminogen are immunochemically related. Biochim Biophys Acta 1988; 960: 91–7
   PubMedGoogle Scholar
• März W, Trommlitz M, Scharrer I, et al. Apolipoprotein(a) concentrations are not related to the risk of venous thrombosis. Blood Coag Fibrinol 1991; 2: 595–9
   PubMed Web of Science ®Google Scholar
• Donders S HJ, Lustermans F AT, Van Wersch J WJ. On lipoprotein(a) and the coagulation/fibrinolysis balance in the acute phase of deep venous thrombosis. Fibrinolysis 1993; 7: 83–6
   Google Scholar
• Palabrica T M, Liu A C, Aronovitz M J, et al. Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nature Medicine 1995; 1: 256–9
   PubMed Web of Science ®Google Scholar
• Grainger D J, Kirschenlohr H L, Metcalfe J C, et al. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993; 260: 1655–8
   PubMed Web of Science ®Google Scholar
• Grainger D J, Kemp P R, Liu A C, et al. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature (London) 1994; 370: 460–2
   PubMed Web of Science ®Google Scholar
• Albers J J, Marcovina SM. Lipoprotein(a) quantification: comparison of methods and strategies for standardization. Curr Opin Lipidol 1994; 5: 417–21
   PubMedGoogle Scholar
• Kostner GM. Standardization of Lp(a) assays. Clin Chim Acta 1992; 211: 191–4
   PubMedGoogle Scholar
• Fless G M, Snyder M L, Furbee J W, Jr., et al. Subunit composition of lipoprotein(a) protein. Biochemistry 1994; 33: 13492–501
   PubMedGoogle Scholar
• Seman L J, Jenner J L, McNamara J R, et al. Quantification of lipoprotein(a) in plasma by assaying cholesterol in lectin-bound plasma fraction. Clin Chem 1994; 40: 400–3
   PubMed Web of Science ®Google Scholar
• Nauck M, Winkler K, Wittmann C, et al. Direct determination of lipoprotein(a) cholesterol by ultracentrifugation and agarose gel electrophoresis with enzymatic staining for cholesterol. Clin Chem 1995; 41: 731–8
   PubMedGoogle Scholar
• Tiran A, Tiran B, Hojas S, et al. Immunoquantification of lipoprotein(a): comparison of nephelometry with electroimmunodiffusion. J Clin Lab Anal 1993; 7: 256–62
   PubMed Web of Science ®Google Scholar
• Vu-Dac N, Chekkor A, Parra H-J, et al. Latex immunoassay of human serum Lp(a+) lipoprotein. J Lipid Res 1985; 26: 267–9
   PubMedGoogle Scholar
• Kronenberg F, Lobentanz E-M, König P, et al. Effect of sample storage on the measurement of lipoprotein(a), apolipoproteins B and A-IV, total and high-density lipoprotein cholesterol, and triglycerides. J Lipid Res 1994; 35: 1318–28
   PubMedGoogle Scholar
• Taddei-Peters W C, Butman B T, Jones G R, et al. Quantification of lipoprotein(a) particles containing various apolipoprotein(a) isoforms by a monoclonal anti-apo(a) capture antibody and a polyclonal anti-apolipoprotein B detection antibody sandwich enzyme immunoassay. Clin Chem 1993; 39: 1382–9
   PubMedGoogle Scholar
• Steyrer E, Durovic S, Frank S, et al. The role of lecithinxholesterol acyltransferase for lipoprotein(a) assembly. Structural integrity of low density lipoproteins is a prerequisite for Lp(a) formation in human plasma. J Clin Invest 1994; 94: 2330–40
   PubMedGoogle Scholar
• Gries A, Nimpf J, Nimpf M, et al. Free and Apo B-associated Lp(a)-specific protein in human serum. Clin Chim Acta 1987; 164: 93–100
   PubMed Web of Science ®Google Scholar
• Albers J J, Marcovina SM. Standardization of Lp(a) measurements. Chem Phys Lipids 1994; 67–8: 257–63
   Google Scholar
• Labeur C, Rosseneu M, Henderson O. International Lp(a) standardization. Chem Phys Lipids 1994; 67–8: 265–70
   Google Scholar
• Tate J. Lipoprotein(a) standardization within Australia and New Zealand. Clin Biochem Revs 1994; 15: 74–81
   Google Scholar
• Campbell B, Tate J, Lepre F, et al. Lipoprotein(a): biology, clinical utility and measurement. Clin Biochem Revs 1992; 13: 55–9
   Google Scholar
• Marcovina S M, Albers J J, Gabel B, et al. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem 1995; 41: 246–55
   PubMed Web of Science ®Google Scholar
• Marcovina S M, Morrisett JD. Structure and metabolism of lipoprotein(a). Curr Opin Lipidol 1995; 6: 136–45
   PubMedGoogle Scholar
• Kronenberg F, König P, Neyer U, et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995; 6: 110–20
   PubMed Web of Science ®Google Scholar
• Rosengren A, Wilhelmsen L, Eriksson E, et al. Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle-aged men. Br Med J 1990; 301: 1248–51
   PubMed Web of Science ®Google Scholar
• Sigurdsson G, Baldursdottir A, Sigvaldason H, et al. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 1992; 69: 1251–4
   PubMedGoogle Scholar
• Cressman M D, Heyka R J, Paganini E P, et al. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992; 86: 475–82
   PubMed Web of Science ®Google Scholar
• Wald N J, Law M, Watt H C, et al. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet 1994; 343: 75–9
   PubMed Web of Science ®Google Scholar
• Schaefer E J, Lamon-Fava S, Jenner J L, et al. Lipoprotein(a) levels and risk of coronary heart disease in men—The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1994; 271: 999–1003
   PubMed Web of Science ®Google Scholar
• Cremer P, Nagel D, Labrot B, et al. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 1994; 24: 444–53
   PubMed Web of Science ®Google Scholar
• Bostom A G, Gagnon D R, Cupples L A, et al. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women: The Framingham Heart Study. Circulation 1994; 90: 1688–95
   PubMed Web of Science ®Google Scholar
• Cantin B, Moorjani S, Després J-P, et al. Lp(a) in ischemic heart disease. The Quebec Cardiovascular Study. J Am Coll Cardiol 1994; 23: 482A, Abstr
   Google Scholar
• Jauhiainen M, Koskinen P, Ehnholm C, et al. Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991; 89: 59–67
   PubMed Web of Science ®Google Scholar
• Ridker P M, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993; 270: 2195–9
   PubMed Web of Science ®Google Scholar
• Alfthan G, Pekkanen J, Jauhiainen M, et al. Relationship of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106: 9–19
   PubMed Web of Science ®Google Scholar
• Dahlen G. The pre-betal lipoprotein phenomenon in relation to serum cholesterol and triglyceride levels, the Lp(a) lipoprotein and coronary heart disease. Acta Med Scand 1974; 1–45, Suppl. 570
   Google Scholar
• Kostner G M, Avogaro P, Cazzolato G, et al. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis 1981; 38: 51–61
   PubMed Web of Science ®Google Scholar
• Sandkamp M, Funke H, Schulte H, et al. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 1990; 36: 20–3
   PubMed Web of Science ®Google Scholar
• Parra H J, Arveiler D, Evans A E, et al. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease: The ECTIM study. Arterioscler Thromb 1992; 12: 701–7
   PubMedGoogle Scholar
• Dahlen G H, Guyton J R, Attar M, et al. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986; 74: 758–65
   PubMed Web of Science ®Google Scholar
• Armstrong V W, Cremer P, Eberle E, et al. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis: dependence on serum LDL levels. Atherosclerosis 1986; 62: 249–57
   PubMed Web of Science ®Google Scholar
• Genest J, Jr., Jenner J L, McNamara J R, et al. Prevalence of lipoprotein (a) [Lp(a)] excess in coronary artery disease. Am J Cardiol 1991; 67: 1039–45
   PubMed Web of Science ®Google Scholar
• Sandholzer C, Saha N, Kark J D, et al. Apo(a) isoforms predict risk for coronary heart disease: a study in six populations. Arterioscler Thromb 1992; 12: 1214–26
   PubMedGoogle Scholar
• Seed M, Hoppichler F, Reaveley D, et al. Relationship of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 1990; 322: 1494–9
   PubMed Web of Science ®Google Scholar
• Wiklund O, Angelin B, Olofsson S-O, et al. Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia. Lancet 1990; 335: 1360–3
   PubMed Web of Science ®Google Scholar
• Craig W Y, Poulin S E, Forster N R, et al. Effect of sample storage on the assay of lipoprotein(a) by commercially available radial immunodiffusion and enzyme-linked immunosorbent assay kits. Clin Chem 1992; 38: 550–3
   PubMed Web of Science ®Google Scholar
• Desmarais R L, Sarembock I J, Ayers C R, et al. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation 1995; 91: 1403–9
   PubMed Web of Science ®Google Scholar
• Hearn J A, Donohue B C, Ba'albaki H, et al. Usefulness of serum lipoprotein (a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1992; 69: 736–9
   PubMed Web of Science ®Google Scholar
• Terres W, Tatsis E, Pfalzer B, et al. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a). Circulation 1995; 91: 948–50
   PubMed Web of Science ®Google Scholar
• Gotoh T, Kuroda T, Yamasawa M, et al. Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). Am J Cardiol 1995; 76: 928–32
   PubMed Web of Science ®Google Scholar
• Sandholzer C, Boerwinkle E, Saha N, et al. Apolipoprotein(a) phenotypes, Lp(a) concentration, and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease. J Clin Invest 1992; 89: 1040–6
   PubMed Web of Science ®Google Scholar
• Költringer P, Jürgens G. A dominant role of lipoprotein(a) in the investigation and evaluation of parameters indicating the development of cervical atherosclerosis. Atherosclerosis 1985; 58: 187–98
   PubMed Web of Science ®Google Scholar
• Asplund K, Olsson T, Viitanen M, et al. Lp(a) lipoprotein in patients with acute stroke. Cerebrovasc Dis 1991; 1: 90–6
   Google Scholar
• Pedro-Botet J, Sentí M, Nogués X, et al. Lipoprotein and apolipoprotein profile in men with ischemic stroke: role of lipoprotein(a), triglyceride-rich lipoproteins, and apolipoprotein E polymorphism. Stroke 1992; 23: 1556–62
   PubMed Web of Science ®Google Scholar
• Jovicic A, Ivanisevic V, Ivanovic I. Lipoprotein(a) in patients with carotid atherosclerosis and ischemic cerebrovascular disorders. Atherosclerosis 1993; 98: 59–65
   PubMedGoogle Scholar
• Nagayama M, Shinohara Y, Nagayama T. Lipoprotein(a) and ischemic cerebrovascular disease in young adults. Stroke 1994; 25: 74–8
   PubMed Web of Science ®Google Scholar
• Shintani S, Kikuchi S, Hamaguchi H, et al. High serum lipoprotein(a) levels are an independent risk factor for cerebral infarction. Stroke 1993; 24: 965–9
   PubMed Web of Science ®Google Scholar
• Ridker P M, Stampfer MJ, Hennekens CH. Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 1995; 273: 1269–73
   PubMed Web of Science ®Google Scholar
• Kronenberg F, Kathrein H, König P, et al. Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler Thromb 1994; 14: 1405–11
   PubMedGoogle Scholar
• Brown S A, Morrisett J D, Boerwinkle E, et al. The relationship of lipoprotein(a) concentrations and apolipoprotein(a) phenotypes with asymptomatic atherosclerosis in subjects of the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb 1993; 13: 1558–66
   PubMedGoogle Scholar
• Tatò F, Keller C, Schuster H, et al. Relationship of lipoprotein(a) to coronary heart disease and duplexsonographic findings of the carotid arteries in heterozygous familial hypercholesterolemia. Atherosclerosis 1993; 101: 69–77
   PubMed Web of Science ®Google Scholar
• Cambillau M, Simon A, Amar J, et al. Serum Lp(a) as a discriminant marker of early atherosclerotic plaque at three extracoronary sites in hypercholesterolemic men. Arterioscler Thromb 1992; 12: 1346–52
   PubMedGoogle Scholar
• Wendelhag I, Wiklund O, Wikstrand J. Atherosclerotic changes in the femoral and carotid arteries in familial hypercholesterolemia: ultrasonographic assessment of intima-media thickness and plaque occurrence. Arterioscler Thromb 1993; 13: 1404–11
   PubMedGoogle Scholar
• Schreiner P J, Momsett J D, Sharrett A R, et al. Lipoprotein[a] as a risk factor for preclinical atherosclerosis. Arterioscler Thromb 1993; 13: 826–33
   PubMedGoogle Scholar
• Rankinen T, Väisänen S, Mercuri M, et al. Apolipoprotein(a), fibrinopeptide A and carotid atherosclerosis in middle-aged men. Thromb Haemost 1994; 72: 563–6
   PubMedGoogle Scholar
• Willeit J, Kiechl S, Santer P, et al. Lipoprotein(a) and asymptomatic carotid artery disease. Evidence of a prominent role in the evolution of advanced carotid plaques: The Bruneck Study. Stroke 1995; 26: 1582–7
   PubMedGoogle Scholar
• Mölgaard J, Klausen I C, Lassvik C, et al. Significant association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication. Arterioscler Thromb 1992; 12: 895–901
   PubMedGoogle Scholar
• Tyrrell J, Cooke T, Reilly M, et al. Lipoprotein [Lp(a)] and peripheral vascular disease. J Intern Med 1992; 232: 349–52
   PubMedGoogle Scholar
• Valentine R J, Grayburn P A, Vega G L, et al. Lp(a) lipoprotein is an independent, discriminating risk factor for premature peripheral atherosclerosis among white men. Arch Intern Med 1994; 154: 801–6
   PubMed Web of Science ®Google Scholar
• Cantin B, Moorjani S, Dagenais G R, et al. Lipoprotein(a) distribution in a French Canadian population and its relationship to intermittent claudication (The Quebec Cardiovascular Study). Am J Cardiol 1995; 75: 1224–8
   PubMedGoogle Scholar
• Callow M J, Verstuyft J, Tangirala R, et al. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a). J Clin Invest 1995; 96: 1639–46
   PubMed Web of Science ®Google Scholar
• Mancini F P, Newland D L, Mooser V, et al. Relative contributions of apolipoprotein(a) and apolipoprotein-B to the development of fatty lesions in the proximal aorta of mice. Arterioscler Thromb Vasc Biol 1995; 15: 1911–6
   PubMedGoogle Scholar
• Lawn R M, Wade D P, Hammer R E, et al. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature (London) 1992; 360: 670–2
   PubMed Web of Science ®Google Scholar
• Kronenberg F, Utermann G, Dieplinger H. Lipoprotein(a) in renal disease. Am J Kidney Dis 1996; 27: 1–25
   PubMed Web of Science ®Google Scholar
• Wanner C, Bartens W. Lipoprotein(a) in renal patients: is it a key factor in the high cardiovascular mortality?. Nephrol Dial Transplant 1994; 9: 1066–8
   PubMedGoogle Scholar
• Kronenberg F. Lipoprotein(a) in renal disease: what we have, what we need, what we can forget. Nephrol Dial Transplant 1995; 10: 766–9
   PubMedGoogle Scholar
• Karádi I, Romics L, Pálos G, et al. Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin. Clin Chem 1989; 35: 2121–3
   PubMed Web of Science ®Google Scholar
• Faucher C, Doucet C, Baumelou A, et al. Elevated lipoprotein (a) levels in primary nephrotic syndrome. Am J Kidney Dis 1993; 22: 808–13
   PubMed Web of Science ®Google Scholar
• Takegoshi T, Kitoh C, Haba T, et al. A study of the clinical significance of lipoprotein(a) in nephrotic syndrome. Jpn J Med 1991; 30: 21–5
   PubMedGoogle Scholar
• Wanner C, Rader D, Bartens W, et al. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med 1993; 119: 263–9
   PubMedGoogle Scholar
• Stenvinkel P, Berglund L, Heimbürger O, et al. Lipoprotein(a) in nephrotic syndrome. Kidney Int 1993; 44: 1116–23
   PubMedGoogle Scholar
• Joven J, Simó JM, Vilella E, et al. Accumulation of atherogenic remnants and lipoprotein(a) in the nephrotic syndrome: relationship to remission of proteinuria. Clin Chem 1995; 41: 908–13
   PubMedGoogle Scholar
• Gansevoort R T, Heeg J E, Dikkeschei F D, et al. Symptomatic antiproteinuric treatment decreases serum lipoprotein(a) concentration in patients with glomerular proteinuria. Nephrol Dial Transplant 1994; 9: 244–50
   PubMedGoogle Scholar
• Dieplinger H, Lackner C, Kronenberg F, et al. Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest 1993; 91: 397–401
   PubMedGoogle Scholar
• Appel G B, Blum C B, Chien S, et al. The hyperlipidemia of nephrotic syndrome: relation to plasma albumin concentration, oncotic pressure and viscosity. N Engl J Med 1985; 312: 1544–8
   PubMed Web of Science ®Google Scholar
• Hirata K, Kikuchi S, Saku K, et al. Apolipoprotein(a) phenotypes and serum lipoprotein(a) levels in maintenance hemodialysis patients with/without diabetes mellitus. Kidney Int 1993; 44: 1062–70
   PubMedGoogle Scholar
• Auguet T, Senti M, Rubies-Prat J, et al. Serum lipoprotein(a) concentration in patients with chronic renal failure receiving hemodialysis: influence of apolipoprotein(a) genetic polymorphism. Nephrol Dial Transplant 1993; 8: 1099–103
   PubMed Web of Science ®Google Scholar
• Webb A T, Reaveley D A, O'Donnell M, et al. Lipoprotein(a) in patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1993; 8: 609–13
   PubMed Web of Science ®Google Scholar
• Barbagallo C M, Averna M R, Sparacino V, et al. Lipoprotein (a) levels in end-stage renal failure and renal transplantation. Nephron 1993; 64: 560–4
   PubMedGoogle Scholar
• Fiorini F, Masturzo P, Mij M, et al. Lipoprotein(a) levels in hemodialysis patients: relationship to glucose intolerance and hemodialysis duration. Nephron 1995; 70: 500–1
   PubMedGoogle Scholar
• Murphy B G, McNamee PT. Apolipoprotein(a) concentration decreases following renal transplantation. Nephrol Dial Transplant 1992; 7: 174–5
   PubMedGoogle Scholar
• Gault M H, Longerich L L, Purchase L, et al. Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature. Nephron 1995; 70: 155–70
   PubMedGoogle Scholar
• Webb A, Misra M, Reaveley D, et al. Effect of change of renal replacement therapy on plasma lipoprotein(a) concentration. Atherosclerosis 1994; 109: 277, Abstr
   Google Scholar
• Black I W, Wilcken D EL. Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism. Clin Chem 1992; 38: 353–7
   PubMed Web of Science ®Google Scholar
• Kronenberg F, König P, Lhotta K, et al. Cyclosporin and serum lipids in renal transplant recipients. Lancet 1993; 341: 765
   PubMedGoogle Scholar
• Yang C W, Kim Y S, Kim S Y, et al. Serum levels of lipoprotein(a) after renal transplantation: short-term follow-up [lett]. Nephron 1994; 67: 364
   PubMedGoogle Scholar
• Segarra A, Chacón P, Martin M, et al. Serum lipoprotein (a) levels in patients with chronic renal failure—evolution after renal transplantation and relationship with other parameters of lipoprotein metabolism: a prospective study. Nephron 1995; 69: 9–13
   PubMedGoogle Scholar
• Azrolan N, Brown C D, Thomas L, et al. Cyclosporin A has divergent effects on plasma LDL cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] levels in renal transplant recipients. Evidence for renal involvement in the maintenance of LDL-C and the elevation of Lp(a) concentrations in hemodialysis patients. Arterioscler Thromb 1994; 14: 1393–8
   PubMedGoogle Scholar
• Kronenberg F, König P, Lhotta K, et al. Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. Arterioscler Thromb 1994; 14: 1399–404
   PubMedGoogle Scholar
• Murphy B G, Yong A, Brown J H, et al. Effect of immunosuppressive drug regime on cardiovascular risk profile following kidney transplantation. Atherosclerosis 1995; 116: 241–5
   PubMedGoogle Scholar
• Segarra A, Chacón P, Vilardell M, et al. Cyclosporin and serum lipids in renal transplant recipients. Lancet 1993; 341: 766
   PubMedGoogle Scholar
• Moore R, Thomas D, Morgan E, et al. Abnormal lipid and lipoprotein profiles following renal transplantation. Transplant Proc 1993; 25: 1060–1
   PubMedGoogle Scholar
• Webb A T, Reaveley D A, O'Donnell M, et al. Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients?. Lancet 1993; 341: 268–70
   PubMedGoogle Scholar
• Hunt B J, Parratt R, Rose M, et al. Does cyclosporin affect lipoprotein(a) concentrations?. Lancet 1994; 343: 119–20
   PubMedGoogle Scholar
• Sturrock N DC, Lang C C, MacFarlane L J, et al. Serial changes in blood pressure, renal function, endothelin and lipoprotein (a) during the first 9 days of cyclosporin therapy in males. J Hypertens 1995; 13: 667–73
   PubMedGoogle Scholar
• Edwards B D, Bhatnagar D, Mackness M I, et al. Effect of low-dose cyclosporin on plasma lipoproteins and markers of cholestasis in patients with psoriasis. Q J Med 1995; 88: 109–13
   Google Scholar
• Wanner C, Bartens W, Walz G, et al. Protein loss and genetic polymorphism of apolipoprotein(a) modulate serum lipoprotein(a) in CAPD patients. Nephrol Dial Transplant 1995; 10: 75–81
   PubMedGoogle Scholar
• Webb A T, Reaveley D A, O'Donnell M, et al. Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy. Nephrol Dial Transplant 1995; 10: 354–7
   PubMedGoogle Scholar
• Oida K, Takai H, Maeda H, et al. Apolipoprotein(a) is present in urine and its excretion is decreased in patients with renal failure. Clin Chem 1992; 38: 2244–8
   PubMed Web of Science ®Google Scholar
• Mooser V, Seabra M C, Abedin M, et al. Apolipoprotein(a) kringle 4-containing fragments in human urine. Relationship to plasma levels of lipoprotein(a). J Clin Invest 1996; 97: 858–64
   PubMed Web of Science ®Google Scholar
• Haffner S M, Morales P A, Stern M P, et al. Lp(a) concentrations in NIDDM. Diabetes 1992; 41: 1267–72
   PubMed Web of Science ®Google Scholar
• Velho G, Erlich D, Turpin E, et al. Lipoprotein(a) in diabetic patients and normoglycemic relatives in familial NIDDM. Diabetes Care 1993; 16: 742–7
   PubMed Web of Science ®Google Scholar
• Imperatore G, Rivellese A, Galasso R, et al. Lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus and borderline hyperglycemia: a population-based study. Metabolism 1995; 44: 1293–7
   PubMedGoogle Scholar
• Heller F R, Jamart J, Honore P, et al. Serum lipoprotein(a) in patients with diabetes mellitus. Diabetes Care 1993; 16: 819–23
   PubMedGoogle Scholar
• Császár A, Dieplinger H, Sandholzer C, et al. Plasma lipoprotein(a) concentration and phenotypes in diabetes mellitus. Diabetologia 1993; 36: 47–51
   PubMedGoogle Scholar
• O'Brien T, Nguyen T T, Harrison J M, et al. Lipids and Lp(a) lipoprotein levels and coronary artery disease in subjects with non-insulin-dependent diabetes mellitus. Mayo Clin Proc 1994; 69: 430–5
   PubMedGoogle Scholar
• Chang C-J, Kao J-T, Wu T-J, et al. Serum lipids and lipoprotein(a) concentrations in Chinese NIDDM patients: relationship to metabolic control. Diabetes Care 1995; 18: 1191–4
   PubMedGoogle Scholar
• Klausen I C, Berg Schmidt E, Lervang H H, et al. Normal lipoprotein(a) concentrations and apolipoprotein(a) isoforms in patients with insulin-dependent diabetes mellitus. Eur J Clin Invest 1992; 22: 538–41
   PubMedGoogle Scholar
• Couper J J, Bates D J, Cocciolone R, et al. Association of lipoprotein(a) with puberty in IDDM. Diabetes Care 1993; 16: 869–73
   PubMedGoogle Scholar
• Salzer B, Stavljenic A, Jürgens G, et al. Polymorphism of apolipoprotein E, lipoprotein(a), and other lipoproteins in children with type I diabetes. Clin Chem 1993; 39: 1427–32
   PubMedGoogle Scholar
• Oscarsson J, Ottosson M, Wiklund O, et al. Low-dose continuously infused growth hormone results in increased lipoprotein(a) and decreased low-density lipoprotein cholesterol concentrations in middle-aged men. Clin Endocrinol 1994; 41: 109–16
   PubMedGoogle Scholar
• James R W, Boemi M, Sirolla C, et al. Lipoprotein (a) and vascular disease in diabetic patients. Diabetologia 1995; 38: 711–4
   PubMed Web of Science ®Google Scholar
• Dubrey S W, Reaveley D R, Seed M, et al. Risk factors for cardiovascular disease in IDDM—a study of identical twins. Diabetes 1994; 43: 831–5
   PubMedGoogle Scholar
• Purnell J Q, Marcovina S M, Hokanson J E, et al. Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM—results from follow-up in the diabetes control and complications trial. Diabetes 1995; 44: 1218–26
   PubMedGoogle Scholar
• Bruckert E, Davidoff P, Grimaldi A, et al. Increased serum levels of lipoprotein(a) in diabetes mellitus and their reduction with glycemic control. JAMA 1990; 263: 35–6
   PubMedGoogle Scholar
• Haffner S M, Tuttle KR, Rainwater DL. Decrease of lipoprotein(a) with improved glycemic control in IDDM subjects. Diabetes Care 1991; 14: 302–7
   PubMedGoogle Scholar
• Makino K, Furbee J W, Jr., Scanu A M, et al. Effect of glycation on the properties of lipoprotein(a). Arterioscler Thromb 1995; 15: 385–91
   Google Scholar
• Doucet C, Huby T, Ruiz J, et al. Nonenzymatic glycation of lipoprotein(a) in vitro and in vivo. Atherosclerosis 1995; 118: 135–43
   PubMedGoogle Scholar
• Jenkins A J, Steele J S, Janus E D, et al. Increased plasma apolipoprotein(a) levels in IDDM patients with microalbuminuria. Diabetes 1991; 40: 787–90
   PubMed Web of Science ®Google Scholar
• Kapelrud H, Bangstad H-J, Dahl-Jorgensen K, et al. Serum Lp(a) lipoprotein concentrations in insulin-dependent diabetic patients with microalbuminuria. Br Med J 1991; 303: 675–8
   PubMed Web of Science ®Google Scholar
• Gall M-A, Rossing P, Hommel E, et al. Apolipoprotein(a) in insulin-dependent diabetic patients with and without diabetic nephropathy. Scand J Clin Lab Invest 1992; 52: 513–21
   PubMed Web of Science ®Google Scholar
• Schnack C, Pietschmann P, Knobl P, et al. Apolipoprotein (a) levels and atherogenic lipid fractions in relation to the degree of urinary albumin excretion in type 2 diabetes mellitus. Nephron 1994; 66: 273–7
   PubMedGoogle Scholar
• Girelli A, Cimino A, Rocca L, et al. Serum lipoprotein (a) is not increased in NIDDM patients with microalbuminuria. Diabetes Care 1994; 17: 456–7
   PubMedGoogle Scholar
• Gruden G, Veglio M, Cavallo-Perin P, et al. Lipoprotein(a) in non-insulin-dependent diabetic patients with normo- and microalbuminuria. Horm Metab Res 1994; 26: 489–90
   PubMedGoogle Scholar
• Zambon S, Baldo-Enzi G, Baiocchi M, et al. Lipoprotein(a) levels in type II diabetic patients are not influenced by metabolic control or by microalbuminuria. Diabetes Care 1994; 17: 1548–9
   PubMedGoogle Scholar
• Jenkins A J, Steele J S, Janus E D, et al. Plasma apolipoprotein (a) is increased in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1992; 35: 1055–9
   PubMed Web of Science ®Google Scholar
• Heesen B J, Wolffenbuttel B HR, Leurs P B, et al. Lipoprotein(a) levels in relation to diabetic complications in patients with non-insulin-dependent diabetes. Eur J Clin Invest 1993; 23: 580–4
   PubMed Web of Science ®Google Scholar
• Hiraga T, Kobayashi T, Okubo M, et al. Prospective study of lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients with diabetes. Diabetes Care 1995; 18: 241–4
   PubMed Web of Science ®Google Scholar
• Haffner S M, Moss S E, Klein B EK, et al. Lack of association between lipoprotein (a) concentrations and coronary heart disease mortality in diabetes: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Metabolism 1992; 41: 194–7
   PubMed Web of Science ®Google Scholar
• Maser R E, Usher D, Becker D J, et al. Lipoprotein(a) concentration shows little relationship to IDDM complications in the Pittsburgh epidemiology of diabetes complications study cohort. Diabetes Care 1993; 16: 755–8
   PubMed Web of Science ®Google Scholar
• Hughes J K, Mendelsohn D. Serum lipoprotein (a) levels in “normal” individuals, those with familial hypercholesterolaemia, and those with coronary artery disease. S Afr Med J 1990; 78: 567–70
   PubMedGoogle Scholar
• Friedlander Y, Leitersdorf E. Segregation analysis of plasma lipoprotein(a) levels in pedigrees with molecularly defined familial hypercholesterolemia. Genet Epidemiol 1995; 12: 129–43
   PubMed Web of Science ®Google Scholar
• Bowden J-F, Pritchard P H, Hill J S, et al. Lp(a) concentration and apo(a) isoform size: relationship to the presence of coronary artery disease in familial hypercholesterolemia. Arterioscler Thromb 1994; 14: 1561–8
   PubMedGoogle Scholar
• Bewu M., Bhatnagar A. D., Durrington D., Serum P N., et al. Lipoprotein(a) in patients heterozygous familial hypercholesterolaemia, their relatives, and unrelated control populations. Arteriosclerosis 1991; 11: 940–6
   Google Scholar
• Knight B L, Perombelon Y FN, Soutar A K, et al. Catabolism of lipoprotein(a) in familial hypercholesterolaemic subjects. Atherosclerosis 1991; 87: 227–37
   PubMed Web of Science ®Google Scholar
• Kostner G M, Gavish D, Leopold B, et al. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 1989; 80: 1313–9
   PubMed Web of Science ®Google Scholar
• Menzel H-J, Dieplinger H, Lackner C, et al. Abetalipoproteinemia with an apoB-100-lipoprotein(a) glycoprotein complex in plasma: indication for an assembly defect. J Biol Chem 1990; 265: 981–6
   PubMedGoogle Scholar
• Perombelon Y FN, Gallagher J J, Myant N B, et al. Lipoprotein(a) in subjects with familial defective apolipoprotein B100. Atherosclerosis 1992; 92: 203–12
   PubMedGoogle Scholar
• Hansen P S, Meinertz H, Jensen H K, et al. Characteristics of 46 heterozygous carriers and 57 unaffected relatives in five Danish families with familial defective apolipoprotein B-100. Arterioscler Thromb 1994; 14: 207–13
   PubMedGoogle Scholar
• Durovic S, März W, Frank S, et al. Decreased binding of apolipoprotein (a) to familial defective apolipoprotein B-100 (Arg3500 Gln). A study of the assembly of recombinant apolipoprotein (a) with mutant low-density lipoproteins. J Biol Chem 1994; 269: 30320–5
   PubMedGoogle Scholar
• Sandholzer C, Feussner G, Brunzell J, et al. Distribution of apolipoprotein(a) in the plasma from patients with lipoprotein lipase deficiency with type III hyperlipoproteinemia: no evidence for a triglyceride-rich precursor of lipoprotein(a). J Clin Invest 1992; 90: 1958–65
   PubMed Web of Science ®Google Scholar
• De Bruin T WA, Van Barlingen H, Van Linde-Sibenius Trip M, et al. Lipoprotein(a) and apolipoprotein B plasma concentrations in hypothyroid, euthyroid, and hyperthyroid subjects. J Clin Endocrinol Metab 1993; 76: 121–6
   PubMed Web of Science ®Google Scholar
• Kung A WC, Pang R WC, Lauder I, et al. Changes in serum lipoprotein(a) and lipids during treatment of hyperthyroidism. Clin Chem 1995; 41: 226–31
   PubMed Web of Science ®Google Scholar
• Hoppichler F, Sandholzer C, Moncayo R, et al. Thyroid hormone (fT4) reduces lipoprotein(a) plasma levels. Atherosclerosis 1995; 115: 65–71
   PubMedGoogle Scholar
• Engler H, Riesen WF. Effect of thyroid function on concentrations of lipoprotein(a). Clin Chem 1993; 39: 2466–9
   PubMed Web of Science ®Google Scholar
• Kurbaan A S, Barbir M, Ilsley G DJ. Normalization of lipoprotein (a) following successful treatment of hypothyroidism. Q. J. Med. 1995; 88: 221–3
   Google Scholar
• Yamamoto K, Ozaki I, Fukushima N, et al. Serum lipoprotein(a) levels before and after subtotal thyroidectomy in subjects with hyperthyroidism. Metabolism 1995; 44: 4–7
   PubMedGoogle Scholar
• Klausen I C, Hegedüs L, Hansen P S, et al. Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with hyperthyroidism. Clin Invest 1995; 73: 41–6
   Google Scholar
• Feely J, Barry M, Keeling P WN, et al. Lipoprotein(a) in cirrhosis. Br Med J 1992; 304: 545–6
   PubMed Web of Science ®Google Scholar
• Van Wersch J WJ. The behavior of lipoprotein(a) in patients with various diseases. Scand J Clin Lab Invest 1994; 54: 559–62
   PubMed Web of Science ®Google Scholar
• Selvais P, Henrion J, Schapira M, et al. La lipoprotéine(a) dans les hépatopathies. Correlation entre sa diminution et l'état fonctionnel du foie. Presse Med 1995; 24: 382–6
   PubMedGoogle Scholar
• Gregory W L, Game F L, Farrer M, et al. Reduced serum lipoprotein(a) levels in patients with primary biliary cirrhosis. Atherosclerosis 1994; 105: 43–50
   PubMed Web of Science ®Google Scholar
• Marth E, Cazzolato G, Bon B, et al. Serum concentrations of Lp(a) and other lipoprotein parameters in heavy alcohol consumers. Ann Nutr Metab 1982; 26: 56–62
   PubMedGoogle Scholar
• Kervinen K, Savolainen MJ, Kesäniemi YA. A rapid increase in lipoprotein (a) levels after ethanol withdrawal in alcoholic men. Life Sci 1991; 48: 2183–8
   PubMed Web of Science ®Google Scholar
• Maeda S, Abe A, Seishima M, et al. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis 1989; 78: 145–50
   PubMed Web of Science ®Google Scholar
• Slunga L, Johnson O, Dahlén G H, et al. Lipoprotein(a) and acute-phase proteins in acute myocardial infarction. Scand J Clin Lab Invest 1992; 52: 95–101
   PubMed Web of Science ®Google Scholar
• Frazer K A, Narla G, Zhang J L, et al. The apolipoprotein(a) gene is regulated by sex hormones and acute-phase inducers in YAC transgenic mice. Nat Genet 1995; 9: 424–31
   PubMed Web of Science ®Google Scholar
• Borba E F, Santos R D, Bonfa E, et al. Lipoprotein(a) levels in systemic lupus erythematosus. J Rheumatol 1994; 21: 220–3
   PubMed Web of Science ®Google Scholar
• Matsuda J, Gotoh M, Gohchi K, et al. Serum lipoprotein(a) level is increased in patients with systemic lupus erythematosus irrespective of positivity of antiphospholipid antibodies. Thromb Res 1994; 73: 83–4
   PubMedGoogle Scholar
• Rantapää-Dahlqvist S, Wållberg-Jonsson S, Dahlén G. Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis 1991; 50: 366–8
   PubMed Web of Science ®Google Scholar
• Takahashi S, Yamamoto T, Moriwaki Y, et al. Increased concentrations of serum Lp(a) lipoprotein in patients with primary gout. Ann Rheum Dis 1995; 54: 90–3
   PubMedGoogle Scholar
• Wright L C, Sullivan D R, Muller M., et al. Elevated apolipoprotein(a) levels in cancer patients. Int J Cancer 1989; 43: 241–4
   PubMed Web of Science ®Google Scholar
• Nakahama H, Nakanishi T, Uyama O, et al. Niceritrol reduces plasma lipoprotein(a) levels in patients undergoing maintenance hemodialysis. Ren Fail 1993; 15: 189–93
   PubMed Web of Science ®Google Scholar
• Carlson L A, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 1989; 226: 271–6
   PubMed Web of Science ®Google Scholar
• Albers J J, Taggart H M, Appelbaum-Bowden D, et al. Reduction of lecithin-cholesterol acyltransferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanazolol. Biochim Biophys Acta 1984; 795: 293–6
   PubMed Web of Science ®Google Scholar
• Crook D, Sidhu M, Seed M, et al. Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid. Atherosclerosis 1992; 92: 41–7
   PubMed Web of Science ®Google Scholar
• Love R R, Wiebe D A, Feyzi J M, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 1994; 86: 1534–9
   PubMed Web of Science ®Google Scholar
• Shewmon D A, Stock J L, Rosen C J, et al. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb 1994; 14: 1586–93
   PubMed Web of Science ®Google Scholar
• Haenggi W, Riesen W, Birkhaeuser MH. Postmenopausal hormone replacement therapy with tibolone decreases serum lipoprotein(a). Eur J Clin Chem Clin Biochem 1993; 31: 645–50
   PubMedGoogle Scholar
• Farish E, Barnes J F, Rolton H A, et al. Effects of tibolone on lipoprotein(a) and HDL subfractions. Maturitas 1994; 20: 215–9
   PubMed Web of Science ®Google Scholar
• Schenck I, Keller C, Hailer S, et al. Reduction of Lp(a) by different methods of plasma exchange. Klin Wochenschr 1988; 66: 1197–201
   PubMedGoogle Scholar
• Bosch T, Thiery J, Gurland H J, et al. Long-term efficiency, biocompatibility, and clinical safety of combined simultaneous LDL-apheresis and haemodialysis in patients with hypercholesterolaemia and end-stage renal failure. Nephrol Dial Transplant 1993; 8: 1350–8
   PubMedGoogle Scholar
• Frank S, Durovic S, Kostner K, et al. Inhibitors for the in vitro assembly of Lp(a). Arterioscler Thromb Vasc Biol 1995; 15: 1774–80
   PubMedGoogle Scholar
• Utermann G. Lipoprotein(a). The metabolic and molecular bases of inherited disease, CR Scriver, AL Beaudet, WS Sly, et al. McGraw-Hill, New York 1995; 1887–912
   Google Scholar
• Couderc R. Member of the Société Franĉaise de Biologie Clinique, Service Biochemie, Hôpital Tenon Paris, Personal communication.
   Google Scholar
• Sakurabayashi I. Department of Clinical Laboratory. Jichi Medical School, Tokyo, Personal communication.
   Google Scholar
• Kronenberg F, et al, Unpublished data.
   Google Scholar
• Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middleaged men. Am J Cardiol 1996; 77: 1179–84
   PubMed Web of Science ®Google Scholar
• Kronenberg F, Trenkwalder E, Dieplinger H, Utermann G. Lipoprotein(a) in stored plasma samples and the ravages of time: why epidemiological studies might fail. Arterioscler Thromb Vasc Biol 1996, in press
   Google Scholar